Want to join the conversation?
$BMY's 1Q16 revenue grew 9% versus 1Q15 due to higher Opdivo, Eliquis and Daklinza product sales. US and Europe revenue rose in the quarter, mainly due to higher demand for Opdivo and Eliquis. Decrease in Rest of the World revenue was driven by lower demand due to increased competition for the Hepatitis C Franchise in Japan.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)